Introduction
Intracranial saccular aneurysms occur in 1% to 2% of the general population and account for approximately 80% to 85% of non-traumatic subarachnoid hemorrhages. 1 A meta-analysis of 33 studies showed a case fatality rate of 8.3% to 66.7% in patients with subarachnoid hemorrhage. 2 Endovascular treatment of intracranial aneurysms emerged in the 1990s with the advent of the Guglielmi detachable coil system (Boston Scientific, Natick, MA, USA), 3 and the use of coil embolization to treat aneurysms has substantially increased after the publication of the results of the International Subarachnoid Aneurysm Trial (ISAT) 4, 5 and the International Study of Unruptured Intracranial Aneurysms (ISUIA). 6 The ISAT results 4 showed that disability or death at 1-year follow-up occurred in 30.9% of patients treated surgically, whereas this figure was only 23.5% in patients treated with coil embolization. Similarly, the ISUIA trial showed the overall morbidity and mortality at 1 year was 12.6% (if no prior history of subarachnoid hemorrhage) for surgical clipping and 9.8% for endovascular coiling. 6 Importantly, crossover, where >50% patients needing aneurysm treatment undergo coiling rather than clipping, is reported to have occurred in the European countries in the 1990s, in the United States in 2004, 7, 8 and in Korea in 2013 ( Figure 1 ). 9 Although endovascular aneurysm treatment options have proven to have better outcomes than clipping for both ruptured and unruptured aneurysms, treating complex aneurysms using conventional coiling is challenging. Specifically, although balloon-assisted or stent-assisted coiling for wide-neck aneurysms shows better occlusion rates and lower recurrence, [10] [11] [12] the recanalization rate of treated large/giant aneurysms can be as high as 18.2%. 13, 14 This observation led to the development of flow diverter, which achieves aneurysm occlusion by endoluminal reconstruction of the vessel wall of the parent artery. 15, 16 The flow diverter is a stent-like structure that redirects blood flow away from the aneurysm depending on its metalto-vessel wall coverage ratio, thereby promoting aneurysm thrombosis. Flow diverters have been successfully used for treating wide-neck, giant, fusiform, and blister-like aneurysms. [15] [16] [17] Recent device innovations have made previously difficult or untreatable aneurysms easy to manage, and novel device designs are being frequently reported. [18] [19] [20] [21] [22] [23] Medtronic (Minneapolis, MN, USA), Stryker (Kalamazoo, MI, USA), Codman Neuro (Los Gatos, CA, USA), and MicroVention (Aliso Viejo, CA, USA) are four large manufactures of neuroendovascular devices. All these companies are located in the USA. The U.S. Food and Drug Administration (FDA) of the USA usually requires adequate evidence from prospective clinical trials to approve new medical devices, whereas in the European Union (EU), clinical trials of effectiveness are generally not required for approval of most devices. 24 Therefore, many new medical devices are usually approved faster in the EU than in the USA. 24 Korea, China, and Japan are considered to be pivotal East Asian countries that play a prominent role in the field of neurointervention; although these countries have a substantial market for medical devices, they rely heavily on imported medical devices. [25] [26] [27] Despite EU and FDA approval, the pre-market access process for a new medical device in the Asian market may be required because ethnic difference may exist in Asian people. Approval authorities usually evaluate high risk devices through a strict regulatory process to detect potential risk arising from devices and to safeguard patient safety. 13, 24, [28] [29] [30] [31] In this article, we review the status of new device development for endovascular treatment of aneurysms and then provide a brief review of market access policies and regulations for importing high-risk medical devices in Korea, China, and Japan.
Methods
We searched the Pubmed, Google, and Google Scholar databases for new devices designed for treating intracranial aneurysms on May 31, 2017. The search terms "aneurysm," "intracranial aneurysm," "cerebral aneurysm," "brain aneurysm," "endovascular," and "device" in "AND" and "OR" combinations were used. Publications or reports published in the last 5 years were preferentially selected, but classically important reports published previously were also included. Improvements in devices, including detachable coils, compliant balloons, and stents, that are routinely used for intracranial aneurysm embolization were excluded. Further, as flow diverters are widely employed for treating wide-necked, giant, fusiform, and blister-like intracranial aneurysms and are used in clinical practice in Asian countries, they were also excluded in this review. [15] [16] [17] Information gathered from the search included pictures and manufacturing and marketing details of each device; these were then matched with the latest published research results and on-going clinical trials for that device.
We obtained information on the administrative processes for new medical device import and approval from the recently updated website of the Korean Ministry of Food and Drug Safety (MFDS), China Food and Drug Administration (CFDA), and Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. Executives and experts from medical companies responsible for registering such devices and obtaining approval for them and physicians using these devices in all three countries were also consulted to verify the content presented in this review. Data from Korea, China, and Japan were compiled and compared based on similar but differently named administrative bodies and the timelines involved. We present data on three products that are commonly used in clinical practice, namely Neuroform (Stryker), Enterprise (Codman Neuro), and Pipeline (Medtronic), as examples to compare the timeline for importing and to understand the differences in approval times among the three countries.
Results and discussion

Part I. New devices for endovascular treatment of intracranial aneurysms
We reviewed only new devices that are conceptually different from those currently being used elsewhere but are not yet available in Korea and found nine such systems: the Woven Endo-Bridge (WEB) for intrasaccular flow disruption, the Medina coil system for saccular filling, the Barrel stent, the Pul- seRider, the pCONus and pCONvas for assisted wide-necked bifurcation aneurysm coiling, the Comaneci for temporary remodeling of aneurysm neck, the eCLIPs for physiological remodeling of bifurcation aneurysms, and the honeycomb microporous covered stent for wide-neck aneurysms. Information on each device is listed in Table 1 and depicted in Figure 2 . Incidentally, seven of these devices are mainly designed for treating wide-necked bifurcation aneurysms, and the covered stent is recommended for treating side-wall aneurysms.
The WEB TM aneurysm embolization system
The WEB (Sequent Medical, Aliso Viejo, CA, USA) is a nitinolbased braided-wire intravascular device designed to be used for treating wide-necked bifurcation aneurysms. 32 It can be introduced into intracranial aneurysms, where it spans the aneurysmal neck to disrupt inflow and reduce intra-saccular flow; thereby, resulting in thrombosis. The smooth and dense surface of the WEB can allow endothelial cells to bridge the neck of the aneurysm and support subsequent vessel wall reconstruction. 33 The device has been progressively developed from a dual-layer version (WEB-DL) to a single-layer version (WEB-SL) that can be used in cylinder-shaped or sphere-shaped configurations (Figure 2A-D) . 23 Numerous clinical studies have been designed to investigate the safety and efficacy of the WEB in the treatment of intracranial wide-necked bifurcation aneurysms. 23, 28, [32] [33] [34] [35] The technical success rate ranged from 92.9% to 98.7%, adequate occlusion at 1-year ranged from 80% to 82%, and procedural morbidity ranged from 1.8% to 2.7%, with no mortalities reported. 23, 28, 32, 33, 35 Thromboembolic events occurred in 4.7% to 15.6% of patients, 23, 28, 32, 34, 35 and adjustment for preoperative and intraoperative antiplatelet treatment showed that the use of any antiplatelet medication was associated with fewer thromboembolic events. 23, 34 Compared with that of the WEB-DL, the WEB-SL with enhanced visualization showed similar rates for technical success, adequate occlusion at 1 year, and procedural morbidity and mortality. 23 
Medina embolization device
The Medina embolization device (MED) is a woven cage that reduces flow into the aneurysm, thereby progressively leading to intrasaccular thrombosis. It is a three-dimensional (3D) coil that is linear in its unconstrained state. When the device is deployed within the aneurysm sac, it expands to its 3D spherical shape as the petals unfold to cover the sac wall and the aneurysm neck ( Figure 2E and F) . 36 Blood flow to the aneurysm is disrupted by the woven material that covers the aneurysm neck; thus, the MED is a device that combines the characteristics of a neck-bridging device and an intrasaccular flow disrupter. The MED is manipulated and deployed through a 0.021" microcatheter and can be mechanically released.
The first clinical experience with Medina was reported in 2015 in a study 36 where nine aneurysms in five patients were selected for treatment with the Medina coil system. The study reported improved circumferential aneurysm filling, with fewer devices and faster operating times. 36 Two more studies reported the use of the Medina device in 15 and 13 aneurysms, respectively, with a technical success rate of 93.3% (14/15) and 100% (13/13), and mid-term occlusion rates of 90.9% (10/11) and 83.3% (10/12), 20, 37 respectively. These studies also reported that one thromboembolic complication was suspected to be caused by the large surface area of contact between the device covering the aneurysm neck and the parent artery but that the patient recovered from the neurological deficit after a bolus of intravenous aspirin. 20 As an average of 2.5 deployments was reported for the Medina coil, there is a possibility of thrombus formation during the deployment of multiple Medina coils due to its thrombogenic design. 20 
Barrel vascular remodeling device system
The use of stent-assisted coiling techniques can be challenging at times due to widening of the vessel lumen, which causes inappropriate abutting of the stent to the vessel wall at the aneurysm level. 18 The Barrel vascular remodeling device (VRD) is a self-expandable, laser-cut stent that has a bulged center section. It is designed as a single device for stent-assisted coil embolization of wide-necked bifurcation aneurysms to lower the metalto-artery ratio and the inherent risk of thromboembolic complications due to multiple stents ( Figure 2G and H) . 18 The initial French Barrel Registry trial study reported a technical success rate of 88.3% (15/17) with no adverse event. 38 In another recently published study, 17 patients with wide-necked bifurcation aneurysms underwent stent-assisted coil embolization with Barrel stents with a technical success rate of 94.1% (16/17) . One ischemic event was observed in one patient that did not result in permanent neurological deficits. 18 
The PulseRider
The PulseRider is another device for treating wide-necked bifurcation aneurysms that are considered challenging to treat. It is available in both "Y" and "T" configurations 22 and acts as a neck bridge in wide-necked aneurysms while protecting the daughter branches during coil embolization ( Figure 2I-L) .
The PulseRider has been widely studied for aneurysm management in several clinical trials in Europe, the UK, and the USA. The number of patients enrolled in each study ranged 
from 10 to 34, the 6-month adequate occlusion rate ranged from 87.9% to 100%, and only a few device-related complications were reported.
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The pCONus and PCANvas
The pCONus is a modified stent-like device designed to assist coil packing of wide-necked bifurcation aneurysms. The distal end of the pCONus has four petals and is implanted inside the aneurysm at its neck, whereas the shaft is anchored in the parent vessel ( Figure 2M and N) . An initial study reported the experience of treating 28 widenecked aneurysms with pCONus-assisted coiling. 40 In 25/28 aneurysms, a single pCONus was used for retaining coils inside the aneurysm sac and protecting the efferent vessels. In two patients, another device was necessary to prevent occlusion of the efferent vessels, whereas in one patient, a second pCONus device was necessary to protect the neck region of the aneurysm. No permanent or transient ischemic symptom was observed, and follow-up angiography between 2 to 19 months showed adequate occlusion in 85.3% patients (19/22) . Although a single pCONus cannot be used to resolve all complex wide-necked aneurysms with arteries deriving from the aneurysm fundus, the use of the pCONus in conjunction with the other stents is considered to be a useful combination in such situations. 21, 41 The pCANvas is an evolution of the pCONus, as it has an additional membrane covering the petals that was specifically designed to modify flow into the aneurysm sac, in addition to supporting coiling ( Figure 2O and P). An in vitro experiment showed that the intraluminal membrane of the pCANvas strongly reduced intra-aneurysmal flow; 40 however, we did not find pertinent clinical or human studies.
The Comaneci device
The Comaneci device is a compliant radiopaque mesh, comparable to a compliant balloon in aneurysm coiling, without the drawback of blocked flow within the parent artery during expansion of the device. Permanent dual antiplatelet therapy is not required since the device is fully removed at the end of the procedure. The extent of expansion can be adjustable by the operator via a slider at the handle ( Figure 2Q ). 42 The initial experience with Comaneci in the treatment of wide-necked aneurysms showed a technical success rate of 77.8% (14/18). One clinically relevant complication (a thrombotic occlusion of the target internal carotid artery) was reported (5.6%), which might be caused by device-related dissection. 42 
The eCLIPs
The eCLIPs was developed as an endovascular clipping device specifically designed to treat bifurcation aneurysms. The eCLIPs has two discrete sections: an anchor segment designed to conform to the architecture of the arterial walls beside the neck of the bifurcation aneurysm and a leaf segment with movable ribs designed to allow a coil delivery catheter to pass through the implanted device to deliver detachable coils. The leaf segment can also be used to divert blood flow and reduce the jet effect into the aneurysm, thus reducing the chances of aneurysm recurrence. 19 The first generation eCLIPs was launched in 2008. 43 The second-generation eCLIPs showed definitive and sustained aneurysm exclusion from circulation and device incorporation into the vessel wall to produce physiological remodeling of the aneurysm during preclinical assessment. 44 A video of the deployment process can be accessed at https://vimeo. com/191976808 ( Figure 2R-T) .
The second-generation eCLIPs was tested in patients for treating wide-necked aneurysms. 44 In an initial clinical series, successful placement of an eCLIPs was achieved in 76% (25/33) of the patients, with an aneurysm occlusion rate of 81.0% (17/21). However, as the delivery method of the eCLIPs is unique, the learning curve showed that successful placement of an eCLIPs requires considerable practice. 44 Furthermore, despite the use of dual antiplatelet therapy, two periprocedural transient ischemic attacks and two asymptomatic thrombotic events occurred in this study involving 25 patients. 44 
The honeycomb microporous covered stent
The novel honeycomb microporous covered stent was developed for treating large or wide-necked cerebral aneurysms. The balloon-expandable stents are covered with a polyurethane film, and the film acquires a honeycomb pattern after expansion (pore diameter of <100 μm, opening area of >30%). The target treatment regions for its clinical application includes the cavernous sinus portion of the internal carotid and the vertebrobasilar arteries. In animal experiments, these stents showed excellent embolization performance at the aneurysm without disturbing branching flow. 45 An investigator-initiated, first-inhuman, clinical trial of the covered stents is currently underway (NCT02907229, Clinical Trials.gov) (Figure 2U-W) .
Part II. Regulatory processes for high-risk medical devices
Medical devices are classified into several categories depending on their degree of invasiveness in the human body. This classification also varies by countries because of differences in regulation policies. Current classifications of medical devices in Korea, China, and Japan are listed and compared in Figure 3 . All devices reviewed in this study are categorized as high-risk intravascular devices (as defined by FDA) 46 and belong to class III/IV in Korea, Class III in China, and Class IV in Japan.
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Korea
In Korea, the MFDS is in charge of approving high-risk devices ( Figure 4A ) 30 and clinical study reports are an essential requirement for technical safety and effectiveness review. If the clinical study reports from other countries comply with MFDS criteria, a Korean clinical study is not required. 25 Applications for reimbursement cost and coverage of a medical device should be submitted to the Ministry of Health and Welfare (MOHW) within 30 days of regulatory approval by the MFDS. 30 The Health Insurance Review and Assessment Services reviews these applications and provides recommendations to the MOHW, which then decides on reimbursement coverage and price. 50, 51 Importantly, devices that do not get approval for reimbursement are generally not allowed to be used in hospitals. Therefore, the potential risk for companies is that although they may have MFDS approval, cost reimbursement can be denied by the MOHW. 52 As per the MFDS website, the registration process for MFDS approval takes <142 workdays (55+77+10), whereas reimbursement approval takes <150 days ( Figure 4A ). However, the actual time taken, including the time for response-to-deficiency letter, vacations, safety, and effectiveness review, is much longer, 30 especially for novel-design devices because they need additional approval from the National Evidence-based Healthcare Collaborating Agency (NECA) ( Figure 4A) . 53 Taking the Pipeline device (an embolization device for large intracranial aneurysm) as an example, we found that the even though the MFDS had given its approval in May 2011, the NECA issued its approval for the new device in October 2012, and the MOHW finally approved its reimbursement in October 2014 ( Figure 5 ). In this process, the implementation of stricter regulations aimed to evaluate the potential benefits and harms of new devices, and to reduce the incidence of safety issue in the future.
China
In China, all class III medical devices should be approved by the CFDA (Figure 4B ). 13 The Center for Medical Device Evaluation (CMDE) is responsible for conducting a dossier review during the medical device registration process, 13 but most class III devices require clinical trials. 27 The application for a clinical trial should be initially submitted to the CFDA, and the clinical trial will be conducted in two or more "National Drug Clinical Study Sites." 27 According to the instructions for clinical trials given by the CFDA, the clinical trial should take at least 9 months, including application time and license registration with the CFDA. 13 However, according to the experience of medical device companies, the entire process, including clinical trial time and application for CFDA license, usually took approximately 3 years. Thus, there seems to be a wide time-lapse between license application and final permission. Once a device gets the CFDA license and permission for sale from the local Commission of Health and Family Planning, it can be introduced into hospitals for clinical use with or without reimbursement ( Figure 4B ). 54 
Japan
Registration of medical devices in Japan generally takes 1 to 3 years depending on device classification. 29 Device regulation in Japan is centrally conducted by the PMDA and the Ministry of Health, Labour and Welfare (MHLW) ( Figure 4C) . 31 The MHLW authorizes new device approvals upon PMDA analysis, which include site inspections and a pre-market review of the new technology. A foreign manufacturer has to appoint a Marketing Authorization Holder (MAH), and the MAH files a pre-market approval application with the PMDA to ultimately obtain approval from the MHLW. 31 Only local companies in Japan with a valid MAH license can import and sell medical products in the Japanese market. Japan requires clinical trials for most new and improved medical devices to be conducted in the Japanese population. 26 Nevertheless, the PMDA often accepts the results 26 The time for regulatory approval takes usually 9 to 18 months based on PMDA website ( Figure 4C ).
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Conclusions
New and innovative endovascular devices facilitate the management of difficult aneurysms and improve clinical outcomes. Although time span between the appearances of new devices is getting shorter worldwide, the possible benefits from fast introduction of devices must be carefully weighed against the risks arising from them as well. Reasonable communication among the appropriate government authorities, manufacturers, and the related medical societies may improve the registration process and reduce safety issue of devices in the future.
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